Decay accelerating factor (CD55): A target for cancer vaccines?

Cancer Research

Volumn 59, Issue 10, 1999, Pages 2282-2286

  Spendlove, Ian ^a   Li, Li ^a   Carmichael, James ^a   Durrant, Lindy G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; COMPLEMENTARY DNA; DECAY ACCELERATING FACTOR; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ARTICLE; CANCER PREVENTION; CANCER THERAPY; CELL LINE; GENETIC TRANSFECTION; IMMUNOTHERAPY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD55; BONE NEOPLASMS; CANCER VACCINES; CHO CELLS; COMPLEMENT SYSTEM PROTEINS; CRICETINAE; CRICETULUS; DNA, COMPLEMENTARY; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; OSTEOSARCOMA; SEQUENCE ANALYSIS; T-LYMPHOCYTES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033563002     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Muller-Eberhard, H. J. Molecular organisation and function of the complement system. Annu. Rev. Biochem., 57: 321-347, 1988.
2. Liszewski, M. K., Farries, T. C., Lublin, D. M., Rooney, I. A., and Atkinson, J. P. Control of the complement system. Adv. Immunol., 61: 201-283, 1996.
3. Juhl, H., Helmig, F., Baltzer, K., Kalthoff, H., Henne-Bruns, D., and Kremer, B. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. J. Surg. Oncol., 64: 222-230, 1997.
4. Lublin, D. M., and Atkinson, J. P. Decay accelerating factor: biochemistry, molecular biology and function. Annu. Rev. Immunol., 7: 35-58, 1989.
5. Embleton, M. J., Gunn, B., Byers, V. S., and Baldwin, R. W. Anti-tumour reactions of monoclonal antibody against a human osteogenic sarcoma cell line. Br. J. Cancer, 43: 582-587, 1981.
6. Price, M. R., Campbell, D. G., Robins, R. A., and Baldwin, R. W. Characteristics of a cell surface antigen defined by an anti-osteogenic sarcoma monoclonal antibody. Eur. J. Cancer Clin. Oncol., 1: 81-90, 1983.
7. Durrant, L. G., Robins, R. A., Armitage, N. C., Brown, A., Baldwin, R. W., and Hardcastle, J. D. Association of antigen expression and DNA ploidy in human colorectal tumours. Cancer Res., 46: 3543-3549, 1986.
8. Durrant, L. G., Robins, R. A., and Baldwin, R. W. Flow cytometric screening of monoclonal antibodies for drug or toxin targeting to human cancer. J. Natl. Cancer Inst., 81: 688-695, 1989.
9. Buckley, D. J., Chapman, M. A., Durrant, L. G., Robins, R. A., and Armitage, N. C. Increased expression of 791t-Gp72 predicts a poor prognosis in colorectal cancer. Gastroenterology, 110: A497-A497, 1996.
10. Farrands, P. A., Perkins, A. C., Pimm, M. V., Hardy, J. D., Embleton, M. J., Baldwin, R. W., and Hardcastle, J. D. Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody. Lancet, 2: 397-400, 1982.
11. Powel, M. C., Perkins, A. C., Pimm, M. V., Aljetaily, M., and Wastie, M. L. Diagnostic imaging of gynecologic tumors with the monoclonal antibody 791T/36. Am. J. Obstet. Gynecol., 157: 28-34, 1987.
12. Armitage, N. C., Perkins, A. C., Pimm, M. V., Farrands, P. A., Baldwin, R. W., and Hardcastle, J. D. Localization of an anti-tumour monoclonal antibody (791T/36) in gastrointestinal tumors. Br. J. Surg., 71: 407-412, 1984.
13. Durrant, L. G., Byers, V. S., Scannon, P. J., Rodvien, R., Grant, K., Robins, R. A., Marksman, R. A., and Baldwin, R. W. Humoral immune responses to Xmmco-791-Rta immunotoxin in colorectal cancer patients. Clin. Exp. Immunol., 75: 258-264, 1989.
14. Austin, E. B., Robins, R. A., Durrant, L. G., Price, M. R., and Baldwin, R. W. Human monoclonal anti-idiotypic antibody to the tumour associated antibody 791T/36. Immunology, 67: 525-530, 1989.
15. Austin, E. B., Robins, R. A., Baldwin, R. W., and Durrant, L. G. Induction of delayed-hypersensitivity to human tumor cells with a human monoclonal antiidiotypic antibody. J. Natl. Cancer Inst., 83: 1245-1248, 1991.
16. Denton, G. W. L., Durrant, L. G., Hardcastle, J. D., Austin, E. B., Sewell, H. F., and Robins, R. A. Clinical outcome of colorectal cancer patients treated with human monoclonal antiidiotypic antibody. Int. J. Cancer, 57: 10-14, 1994.
17. Durrant, L. G., Buckley, T. J. D., Denton, G. W. L., Hardcastle, J. D., Sewell, H. F., and Robins, R. A. Enhanced cell mediated tumour killing in patients immunised with human monoclonal anti-idiotypic antibody 105AD7. Cancer Res., 54: 4837-4840, 1994.
18. Buckley, D. T. J., Robins, R. A., and Durrant, L. G. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7 delays tumor growth by stimulating anti-tumour T cell responses. Hum. Antibody Hybridoma, 6: 68-72, 1995.
19. Van den Eynde, B., and Van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol., 9: 684-693, 1997.
20. Matsudaira, P. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J. Biol. Chem., 261: 10035-10038, 1987.
21. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. Basic local alignment search tool. J. Mol. Biol., 215: 403-410, 1990.
22. Nicholson-Weller, A., and Wang, C. Structure and function of decay-accelerating factor CD55. J. Lab. Clin. Med., 123: 485-491, 1994.
23. Coyne, K. E., Hall, S. E., Thompson, E. S., et al. Mapping of epitopes, glycosylation sites and complement regulatory protein domains in human decay accelerating factor. J. Immunol., 149: 2906-2913, 1992.
24. Shenoy-Scaria, A. M., Kwong, J., Fujita, T., Olszowy, M. W., Shaw, A. S., and Lublin, D. M. Signal transduction through decay accelerating factor. J. Immunol., 149: 3535-3541, 1992.
25. Davis, L. S., Patel, S. S., Atkinson, J. P., and Lipsky, P. E. Decay accelerating factor functions as a signal transducing molecule for human T cells. J. Immunol., 141: 2246-2252, 1988.
26. Hamann, J., Vogel, B., Vanschijndel, G. M. W., and Vanlier, R. A. W. The 7-Span transmembrane receptor Cd97 has a cellular ligand (Cd55, Daf). 3. Exp. Med., 184: 1185-1189, 1996.
27. Finberg, R. W., White, W., and Nicholson-Weller, A. Decay accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J. Immunol., 149: 2055-2060, 1992.
28. Ruiz, P., Wolkowicz, R., Waisman, A., Hirshberg, D. L., Carmi, P., Erez, N., Garren, H., Herkel, J., Karpuj, M., Steinman, L., Rotter, V., and Cohen, I. Idiotypic immunisation induces immunity to mutant p53 and tumour rejection. Nat. Med., 4:710-712, 1998.
29. Chatterjee, S. K., Tripathi, P. K., Chakraborty, M., Yannelli, J., Wang, H., Foon, K., Maiter, C. C., Blalock, E., and Bhattacharya-Chatterjee, M. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody. Cancer Res., 58: 1217-1224, 1998.
30. Fagerberg, J., Steinitz, M., Wigzell, H., Askelof, P., and Mellstedt, H. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc. Natl. Acad. Sci. USA, 92: 1-5, 1995.